Meta-analytic review of semaglutide safety and efficacy in T2D consolidates evidence across trials, confirming robust glucose-lowering and weight benefits with manageable safety.
Key findingMeta-analytic review of semaglutide safety and efficacy in T2D consolidates evidence across trials,
What the researchers found
Meta-analytic review of semaglutide safety and efficacy in T2D consolidates evidence across trials, confirming robust glucose-lowering and weight benefits with manageable safety.
Why it matters
Relevant to peptide therapeutics.
How the study worked
In publication.
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
A meta-analytic review of the safety and efficacy of semaglutide in type 2 diabetes mellitus and chronic kidney disease patients.
Annals of medicine and surgery (2012), 87(4), 2278-2285
Citation
Ashraf, Taimoor; Bai, Shevita; Kumar, Aashish; Subhash Sagar, Raja; Saloni, Fnu; Kumar, Anesh; Kumar, Rohet; Pahwani, Ashvin; Kumar, Vikash; Hassaan, Muhammad; Khatri, Govinda; Jabbar, Maheen; Deepak, Fnu; Abdella Yusuf, Salih. (2025). A meta-analytic review of the safety and efficacy of semaglutide in type 2 diabetes mellitus and chronic kidney disease patients.. Annals of medicine and surgery (2012), 87(4), 2278-2285. https://doi.org/10.1097/MS9.0000000000003126